Beschreibung
Pantoprazole has minimal CYP2C19 inhibitory activity compared with omeprazole, making it the preferred PPI choice in patients on clopidogrel.
Mechanismus
Pantoprazole does not significantly inhibit CYP2C19, so clopidogrel bioactivation is largely preserved compared with omeprazole or esomeprazole.
Klinische Bedeutung
Observational data suggest no significant increase in cardiovascular events with pantoprazole + clopidogrel; this interaction is less clinically significant than the omeprazole-clopidogrel combination.
Maßnahmen
Pantoprazole is the preferred PPI for gastroprotection in patients on clopidogrel; routine monitoring is not required beyond standard care.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.